Medicus Pharma acquired 98.6% of Antev shares on September 2, 2025. The event also noted that Patrick J. Mahaffy was the former CEO of Clovis Oncology.
2 reports, 1 independent
Updated Sep 2
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Medicus Pharma acquired 98.6% of Antev shares on September 2, 2025. The event also noted that Patrick J. Mahaffy was the former CEO of Clovis Oncology.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Medicus Pharma appointed a Chief Medical Officer to lead Antev Limited's clinical program.Sub-event
Medicus Pharma acquired Antev shares; Mahaffy was former CEO of Clovis Oncology.1 source
Keep exploring
The entities involved
-
Clovis Oncology
small pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- NewsfileMedicus Pharma Ltd. Completes Acquisition of Antev Limited Antev is developing Teverelix, a next generation GnRH Antagonist, as a first in class market product for Acute Urinary Retention (AURr) and
- Unknown outlet